Responses to Treatment With Teriparatide in Patients With Atypical Femur Fractures Previously Treated With Bisphosphonates
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
If oversuppression of bone turnover explained the association between bisphosphonate use and atypical subtrochanteric femur fractures (AFF), this could be reversed with anabolic treatment such as teriparatide. We conducted a prospective, open-label study in patients previously treated with bisphosphonates who sustained AFF, examining the response to 24-month treatment with teriparatide on bone mineral density (BMD), trabecular bone score (TBS), bone turnover markers (BTM), and fracture healing as well as quantitative histomorphometry. We studied 14 patients. Baseline BMD, BTM, and TBS varied widely. On initial bone biopsies, 12 of 14 patients showed tetracycline labels, but mineralizing surface/bone surface was below published normal values in all but 2. Lumbar spine BMD increased significantly at month 24 (6.1% ± 4.3%, p < 0.05 versus baseline), whereas total hip BMD and TBS did not change significantly. Changes in BTM occurred as reported previously for patients without AFF treated with teriparatide after prior bisphosphonate treatment. At month 24, fractures were healed in 6 patients, showed partial healing in 3, were unchanged in 2, and showed nonunion in 1. In a patient with two fractures, the fracture that occurred before teriparatide treatment was reported as healed, but the fracture that occurred while on treatment showed only partial healing. Bisphosphonate-treated patients who sustain AFF show heterogeneity of bone turnover. Treatment with teriparatide resulted in increases in BTM and lumbar spine BMD, as has been reported for patients without AFF. There was no significant effect of teriparatide on hip BMD, mineralizing surface to bone surface (MS/BS), or TBS and no consistent effect on fracture healing. In the context of a patient who has experienced an AFF after receiving bisphosphonate treatment, therapy with teriparatide for 24 months would be expected to increase BMD and BTM (and probably reduce the risk of fractures resulting from osteoporosis) but should not be relied on to aid in healing of the AFF. © 2017 American Society for Bone and Mineral Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147 · cited 3×
“Features of AFF include the subtrochanteric location and 4 of 5 major features (minimal or no trauma; transverse or short oblique configuration; little or no comminution; incomplete fractures show a lateral stress reaction, whereas complete fractures may show a medial spike).((4,5)) An increasing number of AFFs have b…”
BackgroundTrabecular bone score (TBS): available knowledge, clinical relevance, and future prospects
the Scientific Committee of the GRIO (Groupe de Recherche et d’Information sur les Ostéoporoses), Bousson, V., Bergot, C., Sutter, B., Levitz, P., & Cortet, B. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1824-6 · Cited by 250 · cited 2×
“All participants had documented AFF that met ASBMR criteria((5)) and had longitudinal and systematic measurements of BMD, BTM, sequential radiological assessment of both femurs by X-ray and computerized tomography (CT), trabecular bone score (TBS),((26)) and paired quantitative histomorphometric assessment of iliac cr…”
BackgroundMiyakoshi, N., Aizawa, T., Sasaki, S., Ando, S., Maekawa, S., Aonuma, H., Tsuchie, H., Sasaki, H., Kasukawa, Y., & Shimada, Y. (2015) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0617-3 · Cited by 114
Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene
Vestergaard, P., Schwartz, F., Rejnmark, L., & Mosekilde, L. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1512-y · Cited by 62
Cited by
Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
“There is evidence that using anabolic therapy when AFF is diagnosed accelerates fracture healing (325-327).”
Self-citationCamacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Self-citationBakr, M. M., Kelly, W. L., Brunt, A. R., Paterson, B. C., Massa, H. M., Morrison, N. A., & Forwood, M. R. (2020) · JBMR Plus · doi:10.1002/jbm4.10387 · Cited by 4
“There is debate as to whether the improved healing of AFF was because of teriparatide treatment, the discontinuation of BPs, or both factors combined.((68)) Furthermore, a reduction in the incidence of AFF by 70% per year was reported, when BPs were ceased.”
Background
Metadata
- Authors
- Watts, N. B., Aggers, D., McCarthy, E. F., Savage, T., Martinez, S., Patterson, R., Carrithers, E., & Miller, P. D.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-01-10
- Volume
- 32
- Issue
- 5
- Pages
- 1027-1033
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2570054804
- Cited by
- 69
- References
- 5
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.